Aimbio

AimBio is a South Korean biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) and antibody therapeutics for refractory brain diseases and oncology. Spun off from the Samsung Medical Center, the company leverages its proprietary Brain-On-a-chip platform to identify novel targets and validate drug efficacy in patient-derived cells. Its lead candidate, AMB302, is an FGFR3-targeting ADC designed to treat glioblastoma and bladder cancer. The company's approach integrates genomic data and patient-derived cell libraries to overcome the limitations of traditional drug discovery in neuro-oncology. AimBio maintains strategic collaborations with global partners, such as Junshi Biosciences, to advance its pipeline of precision medicines. The firm is positioned as a leader in the Korean biotech ecosystem for its focus on high-unmet-need indications like glioblastoma multiforme.